On Mar. 3, 1989, the U.S. Food and Drug Administration (FDA) approved Bristol-Myers’ PARAPLATIN (carboplatin) for the treatment of recurrent ovarian cancer. 

PARAPLATIN is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate.